Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Ibrahim, Amr R., Paliompeis, Christos, Bua, Marco, Milojkovic, Dragana, Szydlo, Richard, Khorashad, Jamshid S., Foroni, Letizia, Reid, Alistair, de Lavallade, Hugues, Rezvani, Katayoun, Dazzi, Francesco, Apperley, Jane F., Goldman, John M., Marin, David
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2010
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143154/
https://ncbi.nlm.nih.gov/pubmed/20833982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-06-291922
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires